Related Experiment Video
Updated: Aug 7, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
[Molecular-targeted agents in breast cancer]
Yutaka Tokuda1, Yuki Saito, Yasuhiro Suzuki
1Dept. of Breast and Endocrine Surgery, Tokai University School of Medicine.
Abstract:
Recently, molecular-biological analyses of the mechanisms of cancer development have created new anticancer agents, molecular-targeted agents. Among them, the humanized anti-HER 2 monoclonal antibody, trastuzumab (Herceptin), has been available for clinical use in metastatic breast cancer in Japan since June, 2001. Now, it has become one of the key drugs for metastatic breast cancer. Recently, large-scale randomized trials revealed its usefulness in the adjuvant setting of postoperative breast cancer. Furthermore, a new anti-angiogenic agent, bevacizumab, showed significant survival benefits with paclitaxel in metastatic breast cancer. This paper reviews the details of these molecular-targeted agents are reviewed in clinical studies.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs that Stabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers